Young People and Illness Management and Recovery (IMR)
Young People's Experiences of Illness Management and Recovery (IMR) - an Explorative Study
The study is a combined clinical patient outcome study and a health-services research sub-study. Illness management and recovery (IMR) constitutes an evidence-based practice with 11 modules focusing on personal recovery developed for adults with severe mental health illnesses. IMR can be offered in groups or individually, once a week for 10-12 months.
Little is known about how young people experience the utility of IMR treatment groups in child and adolescent mental health outpatient clinics. The primary aim is to explore in-depth how the participants experience the utility of the IMR approach. The health research sub-study will provide new insights into the IMR implementation process in outpatient clinics for adolescents.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
IMR has previously been implemented for adolescents in an inpatient unit in the hospital's catchment area. In order to offer the same treatment to all young patients, IMR treatment groups will be established in 4 out of 7 outpatient clinics in the hospital's catchment area. Participants belonging to the clinics in which no IMR treatment groups are being established will be invited to participate in IMR groups in clinics nearby.
The primary aim is to gain new insight into how young people experience the utility of IMR treatment groups conducted in outpatient practices and, if relevant, which changes could be made to adapt IMR more to young people. To explore how the participants experience the utility of IMR treatment groups, a qualitative focus-group study, consisting of a maximum of 5 focus-group interviews will be conducted. The participants in each IMR treatment group will be offered treatment once a week up to 10-12 months. To establish an IMR treatment group a minimum of 4 patients and a maximum of 8 participants must participate. Participants are mainly being included in the IMR treatment groups at the two primary admissions to each treatment group. Thus, some of the participants in the focus-groups may have participated in IMR groups for less than 10-12 months.
Secondary outcomes are related to fidelity to the model and the extent to which IMR treatment groups are implemented at an organizational level. The treatment groups will be led by trained IMR-therapists employed in inpatient units, together with therapists in training who are employed in outpatient clinics. Leaders and other clinicians in the outpatient clinics will contribute knowledge about the extent to which core components of IMR are being implemented, as well as information relating to quality improvement and individual adjustment. Two of the out-patient clinics in which no IMR group is being established will be included in the sub-study. The clinics will receive written feedback after each measurement time to support quality improvement.
The goal is to include up to 48 participants receiving IMR treatment in outpatient clinics. Up to 8 hospitalized participants will participate in a pilot focus-group interview. In the sub-study, a maximum of 16 IMR therapists, trained and in training, and up to 24 staff members will be invited to participate.
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Viken, Noruega
- Akershus universitetssykehus
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria Patients:
Outpatient units:
- Included in the IMR group in one of the outpatient clinics
- Able to give informed consent
Inpatient unit (focus group):
- 13-17 years of age
- Current or previous patient
- Able to understand and speak Norwegian
- Able to give informed consent
Exclusion criteria (inpatient unit)
- Younger than 13 years
- Mental retardation
- Manic phase
Inclusion Criteria: IMR therapists:
- IMR therapist leading IMR treatment groups in one of the participating outpatient clinics
- Trained or training in IMR
- Employed at the Department for Child and Adolescent Mental Health Services at Akershus University Hospital.
Inclusion Criteria: Other staff members
• Employed at the Department for Child and Adolescent Mental Health Services at Akershus University Hospital.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
IMR patients
Patients from outpatient clinics receiving IMR from trained IMR therapists and IMR therapists in training.
|
Treatment given in groups, weekly for 10-12 months.
Otros nombres:
|
|
IMR therapists and other staff
Clinic leaders, IMR therapists and other staff participating in semi-structured individual or group interviews.
|
Semi-structured individual or group interviews conducted three times with staff on each participating outpatient clinic.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Focus-group interview aiming to explore the significance of the participant's own understanding of and knowledge about the disorder.
Periodo de tiempo: End of treatment group, on average 11 months.
|
Focus-group interviews when the treatment group has come to an end aimed at exploring different perspectives on IMR treatment.
|
End of treatment group, on average 11 months.
|
|
Focus-group interview aiming to explore the impact of the IMR treatment on dealing with everyday life.
Periodo de tiempo: End of treatment group, on average 11 months.
|
Focus-group interviews when the treatment group has come to an end aimed at exploring different perspectives on IMR treatment.
|
End of treatment group, on average 11 months.
|
|
Focus-group interview aiming to explore the importance of meeting other young people in the same situation.
Periodo de tiempo: End of treatment group, on average 11 months.
|
Focus-group interviews when the treatment group has come to an end aimed at exploring different perspectives on IMR treatment.
|
End of treatment group, on average 11 months.
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The Illness Management and Recovery Scale (IMRS)
Periodo de tiempo: Baseline (0 months), 6 and 12 months.
|
A 15-item scale that assesses illness self-management on a 5-point Likert scale where 5 indicates full self-management and 0 indicates no self-management.
The scale measures consumer behavior relating to core components in the IMR program.
The scale includes parallel clinician and consumer versions.
Participants participating in IMR groups for less than 10-12 months will attend fewer measuring times.
|
Baseline (0 months), 6 and 12 months.
|
|
The Illness Management Fidelity Scale
Periodo de tiempo: Baseline (0 months), 6 and 12 months.
|
Assesses the degree of fidelity with 13 items on a 5-point Likert scale where 5 indicates full implementation and 0 indicates no implementation.
Filled in by researchers on the basis of a semistructured interview with staff members.
|
Baseline (0 months), 6 and 12 months.
|
|
General Organizational Index
Periodo de tiempo: Baseline (0 months), 6 and 12 months.
|
A 12-item scale measuring organizational outcome of implementation, on a 5-point Likert scale where 5 indicates full implementation and 0 indicates no implementation.
The scale is filled in by researchers on the basis of a semi-structured interview with staff members.
|
Baseline (0 months), 6 and 12 months.
|
|
Attendance registration
Periodo de tiempo: Baseline (0 months), 3, 6, 9 and 12 months.
|
The number of sessions the patients are attending in the IMR treatment group.
|
Baseline (0 months), 3, 6, 9 and 12 months.
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Mapping the total number of patients identified receiving a psychosis-related diagnosis within the categories F 20-39 (ICD 10) for the years 2021-2023.
Periodo de tiempo: End of treatment group, on average of 11 months.
|
The numbers will be displayed in the form of statistics obtained in the hospital.
The numbers will be compared to what has been reported in the annual reports for the clinics from 2015 to 2020.
|
End of treatment group, on average of 11 months.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Anne-Lise Holmesland, PhD, University Hospital, Akershus
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 20/09657
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .